The $11.75-per-share offer for Mississauga, Ontario-based Novadaq was a 95.8% premium on its $6 closing price on June 16, providing a company valuation of roughly $701 million. The deal included some $47 million in net cash, the companies said.
The Kalamazoo, Mich.-based company said that the transaction is expected to be dilutive to its 2017 adjusted net earnings per diluted share by 3¢-5¢, which it originally indicated in June, according to a press release.
Canadian courts approved the sale to Stryker in early August, a month after proxy advisors Institutional Shareholder Services and Glass, Lewis & Co. backed the deal, which had to win over at least 66⅔% of the quorum at a shareholders meeting August 4. A 98.7% majority of shares represented at that meeting voted to approve the deal, which is a 95.8% premium on NVDQ’s June 16 closing price, the day before the deal was announced.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.